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Background
HIV infection, combined antiretroviral therapy (cART)
and metabolic syndrome are associated to an increased
cardiovascular risk (CVR). Cystatin C, a low molecular
weight cysteine protease inhibitor involved in vascular
extracellular matrix remodelling, is considered a novel
marker of kidney function and CVR in general popula-
tion. To value the role of cystatin C in HIV infected
patients without chronic kidney disease treated with
cART subdivided for CVR.
Methods
56 Caucasian HIV+ cART treated patients without
chronic kidney disease were subdivided by means of
Framingham score into two groups: A) 15 patients with
“high” CVR, and B) 41 patients with “low” CVR. Viro-
immunological parameters, triglycerides (TGs), total
cholesterol (TCh), HDL (HDL-C) and LDL (LDL-C)
cholesterol, blood pressure, microalbuminuria, GFR-
MDRD, fasting glucose, insulinemia, HOMA-IR, CRP,
cystatin C, IL-18, IL-6, body mass index (BMI) and
waist-to-hip ratio (WHR) were measured.
Results
The two groups were homogeneous for years of cART,
CD4- and CD8- T cell count, viral load. Group A
showed statistically higher levels of BMI (p < 0.009),
WHR (p < 0.001), TCh (p < 0.001), LDL-C (p < 0.001),
TGs (p < 0.02), systolic blood pressure (p < 0.001), fast-
ing glucose (p < 0.002), insulinemia (p < 0.008),
HOMA-IR (p < 0.001), cystatin C (p < 0.001), microal-
buminuria (p < 0.001), IL-6 (p < 0.03) and IL-18 (p <
0.01). The GFR-MDRD and the inflammatory index
CRP did not show significant differences between the
two groups. Finally, data showed a positive correlation
between CVR and cystatin C (r = 0.39 and p = 0.003).
Discussion
In the present study it is remarkable that patients in “high”
CVR group showed higher values of cystatin C and micro-
albuminuria even though kidney function was normal.
Also microalbuminuria, besides its relation with progres-
sive renal damage, has been found to be an independent
factor of CVR and mortality in the general population.
Furthermore, the positive correlation between CVR and
cystatin C found in this study for the first time in HIV
positive patients, is in accord with the evidence existing in
literature of a strong association between cystatin C and
CVR in the general population. These findings may indi-
cate that cystatin C and microalbuminuria could serve as
early markers of enhanced CVR, besides of renal compli-
cations, in the HIV-infected population.
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